Pharmaceuticals

mRNA Therapeutics CDMO Market Anticipated to Record Steady Gains, Advancing to $8.26 Billion by 2030

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the mrna therapeutics cdmo market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the mRNA Therapeutics CDMO Market?

The mrna therapeutics cdmo market size has seen rapid expansion in recent years. It is forecast to increase from $4.74 billion in 2025 to $5.31 billion in 2026, registering a compound annual growth rate (CAGR) of 12.0%. The expansion observed in the historic period can be ascribed to factors including the restricted availability of specialized mrna cdmo services, reliance on internal pharmaceutical manufacturing, the rising number of infectious disease outbreaks, the adoption of early-stage analytical testing, and the broadening of academic and research collaborations.

The mrna therapeutics cdmo market is projected to experience swift expansion in the upcoming years, set to reach a value of $8.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. Several factors are driving this expansion during the forecast period, including increased funding for mrna therapeutics pipelines, progress in plasmid DNA and mrna synthesis technologies, the rise of cancer immunotherapy and protein replacement treatments, a growing need for fill-finish offerings, and the proliferation of collaborations between biotech firms and CDMOs. Key trends anticipated during this period involve a heightened requirement for outsourced mrna development and production, a stronger emphasis on lipid nanoparticle (LNP) formulation techniques, the enlargement of viral vaccine and cancer immunotherapy pipelines, strengthened regulatory adherence and quality control protocols, and the increasing utilization of analytical and bioanalytical laboratory provisions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp

What Drivers Are Supporting Technological Adoption In The mRNA Therapeutics CDMO Market?

The rising incidence of chronic and infectious diseases is projected to drive the expansion of the mRNA therapeutics CDMO market in the coming years. These diseases include enduring conditions like diabetes, cardiovascular disorders, and asthma, along with illnesses caused by viruses, bacteria, and parasites that spread directly or indirectly between people. The increase in these health issues is partly due to aging populations, who are more prone to both long-term conditions and infections. mRNA therapeutics CDMOs contribute to combating chronic and infectious diseases by offering comprehensive development and manufacturing services, thus speeding up the delivery of precise, individualized mRNA treatments to patients. For example, the World Health Organization, a Switzerland-based international public health body, reported in October 2024 that new tuberculosis diagnoses reached approximately 8.2 million people in 2023, an increase from about 7.5 million in 2022, underscoring the worsening global burden of infectious diseases. Consequently, the increasing prevalence of chronic and infectious diseases is fueling the growth of the mRNA therapeutics CDMO market.

Which Segments Are Contributing To The Growth Of The mRNA Therapeutics CDMO Market?

The mrna therapeutics cdmo market covered in this report is segmented –

1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services

2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases

3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies

4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations

Subsegments:

1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support

2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services

3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing

What Upcoming Trends Are Likely To Define The Future Path Of The mRNA Therapeutics CDMO Market?

Companies active in the mRNA therapeutics CDMO market are concentrating on creating novel solutions, like in situ nanomedicine vaccines, to improve the efficacy and accuracy of mRNA-based vaccines by stimulating the immune system precisely. This type of vaccine represents an advanced mRNA therapeutic, engineered to produce nanomedicines directly inside the patient, thereby allowing for specific delivery and personalized immune responses via engineered transgene expression. As an example, in January 2025, the Canadian biotechnology firm, Esphera SynBio Inc., initiated a project with backing from the CQDM Quantum Leap program. The goal of this undertaking is to upgrade existing first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by integrating unique transgene designs that trigger the body’s own production of immune-stimulating nanomedicines. This strategy facilitates exact antigen delivery and customized immune reactions, positioning the technology as a potential significant advance in vaccine development.

Who Are The Prominent Global Companies Shaping The mRNA Therapeutics CDMO Market Landscape?

Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The mRNA Therapeutics CDMO Market?

North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized mRNA Therapeutics CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25841&type=smp

Browse Through More Reports Similar to the Global mRNA Therapeutics CDMO Market 2026, By The Business Research Company

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Mrna Cancer Vaccines And Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-cancer-vaccines-and-therapeutics-global-market-report

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795